Literature DB >> 27826702

Structural Analysis of the Histamine H1 Receptor.

Mitsunori Shiroishi1,2, Takuya Kobayashi3,4,5.   

Abstract

The crystal structure of the human histamine H1 receptor (H1R) has been determined in complex with its inverse agonist doxepin, a first-generation antihistamine. The crystal structure showed that doxepin sits deeply inside the ligand-binding pocket and predominantly interacts with residues highly conserved among other aminergic receptors. This binding mode is considered to result in the low selectivity of the first-generation antihistamines for H1R. The crystal structure also revealed the mechanism of receptor inactivation by the inverse agonist doxepin. On the other hand, the crystal structure elucidated the anion-binding site near the extracellular portion of the receptor. This site consists of residues not conserved among other aminergic receptors, which are specific for H1R. Docking simulation and biochemical experimentation demonstrated that a carboxyl group on the second-generation antihistamines interacts with the anion-binding site. These results imply that the anion-binding site is a key site for the development of highly selective antihistamine drugs.

Entities:  

Keywords:  Crystal structure; Doxepin; First-generation antihistamines; Histamine H1 receptor; Receptor inactivation mechanism; Receptor selectivity of antihistamines

Mesh:

Substances:

Year:  2017        PMID: 27826702     DOI: 10.1007/164_2016_10

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  2 in total

1.  Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma.

Authors:  Jing Zhao; Yiran Hou; Chun Yin; Jing Hu; Tian Gao; Xiaojun Huang; Xiaohong Zhang; Jinliang Xing; Jiaze An; Shaogui Wan; Jibin Li
Journal:  Oncogene       Date:  2019-11-18       Impact factor: 9.867

Review 2.  Melanocortin-4 receptor complexity in energy homeostasis,obesity and drug development strategies.

Authors:  Munazza Tamkeen Fatima; Ikhlak Ahmed; Khalid Adnan Fakhro; Ammira Sarah Al-Shabeeb Akil
Journal:  Diabetes Obes Metab       Date:  2022-01-11       Impact factor: 6.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.